Mirum Pharmaceuticals (MIRM) Competitors

$100.74 +3.80 (+3.91%)

As of 02:11 PM Eastern

MIRM vs. INSM, BNTX, MRNA, ROIV, and VTRS

Should you buy Mirum Pharmaceuticals stock or one of its competitors? MarketBeat compares Mirum Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mirum Pharmaceuticals include Insmed (INSM), BioNTech (BNTX), Moderna (MRNA), Roivant Sciences (ROIV), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Mirum Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Insmed's net margin of -144.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Insmed had 6 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 16 mentions for Insmed and 10 mentions for Mirum Pharmaceuticals. Insmed's average media sentiment score of 1.16 beat Mirum Pharmaceuticals' score of 0.64 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed presently has a consensus price target of $210.95, suggesting a potential upside of 92.34%. Mirum Pharmaceuticals has a consensus price target of $137.08, suggesting a potential upside of 36.06%. Given Insmed's higher possible upside, research analysts plainly believe Insmed is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.20	-$1.28B	-$5.75	N/A
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A

Summary

Insmed beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

Mirum Pharmaceuticals (NASDAQ:MIRM) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Mirum Pharmaceuticals has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A
BioNTech	$3.25B	7.12	-$1.29B	-$5.88	N/A

BioNTech has a net margin of -44.39% compared to Mirum Pharmaceuticals' net margin of -140.24%. BioNTech's return on equity of -5.30% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
BioNTech	-44.39%	-5.30%	-4.62%

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for BioNTech. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat BioNTech's score of 0.33 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus target price of $137.08, suggesting a potential upside of 36.06%. BioNTech has a consensus target price of $130.60, suggesting a potential upside of 42.82%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Summary

Mirum Pharmaceuticals and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Moderna?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Mirum Pharmaceuticals currently has a consensus price target of $137.08, suggesting a potential upside of 36.06%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 24.70%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Mirum Pharmaceuticals has higher earnings, but lower revenue than Moderna. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A
Moderna	$1.94B	9.69	-$2.82B	-$8.15	N/A

75.3% of Moderna shares are held by institutional investors. 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 10 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Moderna's score of 0.01 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a net margin of -140.24% compared to Moderna's net margin of -143.55%. Mirum Pharmaceuticals' return on equity of -11.28% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Moderna	-143.55%	-26.64%	-19.32%

Mirum Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

64.8% of Roivant Sciences shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

In the previous week, Roivant Sciences had 9 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Roivant Sciences and 10 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Roivant Sciences' score of 0.40 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	2 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a net margin of -140.24% compared to Roivant Sciences' net margin of -6,079.94%. Mirum Pharmaceuticals' return on equity of -11.28% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Mirum Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A
Roivant Sciences	$29.05M	773.99	-$171.98M	-$1.17	N/A

Mirum Pharmaceuticals currently has a consensus target price of $137.08, suggesting a potential upside of 36.06%. Roivant Sciences has a consensus target price of $32.41, suggesting a potential upside of 3.16%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Mirum Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Mirum Pharmaceuticals beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Viatris presently has a consensus price target of $16.43, indicating a potential upside of 0.27%. Mirum Pharmaceuticals has a consensus price target of $137.08, indicating a potential upside of 36.06%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A
Mirum Pharmaceuticals	$521.31M	11.78	-$23.36M	-$13.61	N/A

Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 5 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Viatris' score of 0.07 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.04% compared to Mirum Pharmaceuticals' net margin of -140.24%. Viatris' return on equity of 19.04% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

79.9% of Viatris shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mirum Pharmaceuticals beats Viatris on 10 of the 17 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.14B	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-7.40	18.89	20.88	25.51
Price / Sales	11.78	279.14	520.50	73.06
Price / Cash	1,876.26	125.35	43.18	55.00
Price / Book	25.31	6.90	10.01	7.03
Net Income	-$23.36M	$24.18M	$3.54B	$334.92M
7 Day Performance	-9.56%	0.77%	0.38%	-0.40%
1 Month Performance	7.94%	-0.38%	-0.02%	1.07%
1 Year Performance	127.36%	63.37%	35.07%	34.65%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.0579 of 5 stars	$100.75 +3.9%	$137.08 +36.1%	+113.8%	$6.14B	$521.31M	N/A	140	Analyst Upgrade
INSM Insmed	3.4814 of 5 stars	$117.99 +1.7%	$210.95 +78.8%	+57.5%	$25.14B	$606.42M	N/A	1,664	High Trading Volume
BNTX BioNTech	3.6839 of 5 stars	$92.23 -1.5%	$130.60 +41.6%	-11.2%	$23.69B	$3.25B	N/A	7,807	Gap Up
MRNA Moderna	1.3036 of 5 stars	$50.42 -5.4%	$35.73 -29.1%	+71.9%	$21.14B	$1.94B	N/A	4,700	Insider Trade
ROIV Roivant Sciences	2.0142 of 5 stars	$29.22 -0.6%	$30.55 +4.6%	+193.6%	$21.03B	$29.05M	N/A	860	Trending News Earnings Report Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. INSM, BNTX, MRNA, ROIV, and VTRS

How does Mirum Pharmaceuticals compare to Insmed?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Summary

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. INSM, BNTX, MRNA, ROIV, and VTRS

How does Mirum Pharmaceuticals compare to Insmed?

Which has more volatility and risk, INSM or MIRM?

Is INSM or MIRM more profitable?

Does the media refer more to INSM or MIRM?

Do analysts recommend INSM or MIRM?

Which has higher valuation & earnings, INSM or MIRM?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Which has preferable valuation and earnings, MIRM or BNTX?

Is MIRM or BNTX more profitable?

Which has more volatility and risk, MIRM or BNTX?

Does the media favor MIRM or BNTX?

Do institutionals & insiders hold more shares of MIRM or BNTX?

Do analysts rate MIRM or BNTX?

Summary

How does Mirum Pharmaceuticals compare to Moderna?

Do analysts rate MIRM or MRNA?

Which has stronger valuation & earnings, MIRM or MRNA?

Do institutionals and insiders hold more shares of MIRM or MRNA?

Does the media favor MIRM or MRNA?

Is MIRM or MRNA more profitable?

Which has more risk & volatility, MIRM or MRNA?

Summary

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Do institutionals & insiders have more ownership in MIRM or ROIV?

Which has more volatility & risk, MIRM or ROIV?

Does the media prefer MIRM or ROIV?

Is MIRM or ROIV more profitable?

Which has preferable earnings and valuation, MIRM or ROIV?

Do analysts recommend MIRM or ROIV?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Do analysts rate VTRS or MIRM?

Which has preferable valuation & earnings, VTRS or MIRM?

Which has more volatility & risk, VTRS or MIRM?

Does the media refer more to VTRS or MIRM?

Is VTRS or MIRM more profitable?

Do insiders & institutionals have more ownership in VTRS or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools